Ranolazine Cardioprotection in PCI

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Acute Coronary Syndrome

In brief

The investigators will test if upfront dosing of Ranolazine can reduce myocardial biomarker release (CK-MB, Troponin) post percutaneous coronary intervention (PCI).

Key facts

Study ID

NCT01767987

Run by

Harvey Hahn

People needed

6

Starts

2012-11-01

Expected to finish

2014-04-01

Last updated by the study team

2017-09-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 or older
• Patients undergoing Coronary Angiography with possible PCI
• Able and willing to give consent
• Able to read and write English

You may not qualify if…

• Current EKG or Biomarker of Acute Myocardial Infarction (MI) or Acute Coronary Syndromes (ACS)
• History of Allergy to Ranolazine
• Pregnant or Nursing
• Currently taking Ranolazine

Where it is running

• Kettering Medical Center — Kettering, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.